A medical technology industry organization is urging CMS to quickly revise its national coverage determination for positron emission tomography (PET) scans for detection of beta amyloid plaque, saying the current conditions of coverage limit access to the newly approved Alzheimer’s disease drug that targets such plaque on the brain.